

Author index

Volume 55 (1999)

-
- | | | |
|------------------------------|----------------------------|----------------------------|
| Adelson, M. 55, 63 | García-Gil, L. 55, 127 | Ramos, J.A. 55, 127 |
| A. Meisch, R. 55, 79 | Gastfriend, D.R. 55, 35 | Regan, C.M. 55, 85 |
| Ammerman, R.T. 55, 165 | Gelkopf, M. 55, 63 | Reif, S. 55, 35 |
| Anthony, J.C. 55, 45, 177 | Giesbrecht, N. 55, 53 | Ring-Kurtz, S. 55, 235 |
| Arasteh, K. 55, 117 | Gilvarry, E. 55, 263 | Roche, A. 55, 105 |
| | Gollnisch, G. 55, 145 | Romero, J. 55, 127 |
| Baker, R.W. 55, 1 | Gould, F. 55, 91 | Roset, P.N. 55, 117 |
| Bauman, A. 55, 187 | Grant, K.A. 55, 13 | Rush, C.R. 55, 1 |
| Baumann, P. 55, 137 | Gutowski, W.E. 55, 35 | Rutherford, M. 55, 235 |
| Belding, M.A. 55, 25 | | |
| Bencivengo, M. 55, 91 | Hagan, T.A. 55, 91, 235 | Schottenfeld, R.S. 55, 157 |
| Bleich, A. 55, 63 | Hando, J. 55, 105 | Silas Obot, I. 55, 177 |
| Bodner, G. 55, 63 | Hayward, R. 55, 63 | Solowij, N. 55, 105 |
| Booth, R.E. 55, 69 | Hubbard, S. 55, 177 | Storr, C.L. 55, 45 |
| Bowen, C.A. 55, 13 | | Swadi, H. 55, 209 |
| B. Stewart, R. 55, 79 | Iguchi, M.Y. 55, 25 | |
| | Jaffe, J. 55, 91 | Tarter, R.E. 55, 165 |
| Cami, J. 55, 117 | | Topp, L. 55, 105 |
| Chawarski, M.C. 55, 157 | Kirisci, L. 55, 165 | Trinkoff, A.M. 55, 45 |
| Cherpitel, C.J. 55, 53 | Kwiatkowski, C.F. 55, 69 | Turner, K.H. 55, 35 |
| Christian, J. 55, 263 | | Turner, W.M. 55, 35 |
| Collins, R.L. 55, 145 | Levine, M. 55, 91 | |
| Cox, W.M. 55, 85 | Macdonald, S. 55, 53 | Uehlinger, C. 55, 137 |
| Crome, I.B. 55, 185, 247 | McLellan, A.T. 55, 91, 235 | |
| | Meyers, K. 55, 91, 235 | Wang, N.-s. 55, 79 |
| Dawes, M.A. 55, 165 | Morral, A.R. 55, 25 | Webb, A. 55, 235 |
| Dillon, P. 55, 105 | Morsheimer, E.T. 55, 145 | Weissman, G. 55, 69 |
| Dorn, L.D. 55, 165 | Moss, H.B. 55, 165 | Wells, S. 55, 53 |
| Durell, J. 55, 91 | | Wright, K. 55, 1 |
| | O'Connor, P.G. 55, 157 | |
| Eap, C.B. 55, 137 | | Yao, J.K. 55, 165 |
| | Pakes, J. 55, 157 | Yeates, G.N. 55, 85 |
| Farré, M. 55, 117 | Phongsavan, P. 55, 187 | |
| Felder, C. 55, 137 | Poudevida, S. 55, 117 | Zanis, D. 55, 235 |
| Fernández-Ruiz, J.J. 55, 127 | Powell, K. 55, 137 | Zeitlin, H. 55, 225 |
| Frantz, J. 55, 235 | | |

1871
1872
1873
1874
1875

Subject index

Volume 55 (1999)

Addiction; Algorithm; Automation; Criteria; Matching; Substance abuse **55**, 35

Addiction; Bioavailability; Enantiomer; Health; Intravenous; Methadone; Oral **55**, 137

Addiction; Outpatient; Clinical case management **55**, 91

Addiction Research Center Inventory (ARCI); Spanish version; Subjective effects; Sedatives; Stimulants; Opioids; Drug abuse **55**, 117

Adolescent; Risk factors; Substance use **55**, 209

Adolescents; Assessment; Measurement; Substance abuse; Comprehensive Adolescent Severity Inventory **55**, 235

Adolescent; Substance misuse; Treatment interventions; Outcome **55**, 247

Adolescent; Substance use; Tobacco; Alcohol; Prevalence; Epidemiology **55**, 187

African Americans; Injecting drug use; School dropout; IDU; IVDU; Level of education; Epidemiology **55**, 177

Alcohol; Adolescent; Substance use; Tobacco; Prevalence; Epidemiology **55**, 187

Alcohol; Cognitive processing; Drinkers; Alcohol cues; Stroop paradigm **55**, 85

Alcohol consequences; Nurses; Women; Prevalence; Substance use **55**, 145

Alcohol cues; Cognitive processing; Alcohol; Drinkers; Stroop paradigm **55**, 85

Algorithm; Addiction; Automation; Criteria; Matching; Substance abuse **55**, 35

Assessment; Adolescents; Measurement; Substance abuse; Comprehensive Adolescent Severity Inventory **55**, 235

Automation; Addiction; Algorithm; Criteria; Matching; Substance abuse **55**, 35

Behavioral effects; Cocaine; Humans; Drug abuse; Physiological effects **55**, 1

Benzodiazepines; Methadone maintenance; Sedatives; IDU; Flunitrazepam; Oxazepam; Diazepam; Motivation; Substance abuse **55**, 63

Bioavailability; Addiction; Enantiomer; Health; Intravenous; Methadone; Oral **55**, 137

Buprenorphine; Plasma level; Substance abuse; Opioid maintenance **55**, 157

Cannabinoid receptor binding; Cannabinoids; Δ^9 -Tetrahydrocannabinol; Perinatal exposure; Cannabinoid receptor mRNA levels **55**, 127

Cannabinoid receptor mRNA levels; Cannabinoids; Δ^9 -Tetrahydrocannabinol; Perinatal exposure; Cannabinoid receptor binding **55**, 127

Cannabinoids; Δ^9 -Tetrahydrocannabinol; Perinatal exposure; Cannabinoid receptor binding; Cannabinoid receptor mRNA levels **55**, 127

Clinical case management; Outpatient; Addiction **55**, 91

Cocaine; Humans; Drug abuse; Physiological effects; Behavioral effects **55**, 1

Cognitive processing; Alcohol; Drinkers; Alcohol cues; Stroop paradigm **55**, 85

Comorbid disorders; Substance misuse; Early identification and treatment **55**, 225

Comprehensive Adolescent Severity Inventory; Adolescents; Assessment; Measurement; Substance abuse **55**, 235

Criteria; Addiction; Algorithm; Automation; Matching; Substance abuse **55**, 35

Diazepam; Methadone maintenance; Benzodiazepines; Sedatives; IDU; Flunitrazepam; Oxazepam; Motivation; Substance abuse **55**, 63

Drinkers; Cognitive processing; Alcohol; Alcohol cues; Stroop paradigm **55**, 85

Drug abuse; Addiction Research Center Inventory (ARCI); Spanish version; Subjective effects; Sedatives; Stimulants; Opioids **55**, 117

Drug abuse; Cocaine; Humans; Physiological effects; Behavioral effects **55**, 1

- Drug discrimination;** Ethanol; Pentobarbital; GABA_A positive modulators; NMDA antagonists; 5-HT₁ agonists; Isopropanol; rat 55, 13
- Drug metabolites;** Injuries; Substance use 55, 53
- Drug users;** HIV infected; Risk behaviors; Health-related service utilization 55, 69
- Early identification and treatment;** Substance misuse; Comorbid disorders 55, 225
- Ecstasy;** Patterns of use; Polydrug use; Harm; Intervention preferences 55, 105
- Enantiomer;** Addiction; Bioavailability; Health; Intravenous; Methadone; Oral 55, 137
- Epidemiology;** Adolescent; Substance use; Tobacco; Alcohol; Prevalence 55, 187
- Epidemiology;** Injecting drug use; School dropout; IDU; IVDU; African Americans; Level of education 55, 177
- Ethanol;** Pentobarbital; GABA_A positive modulators; NMDA antagonists; 5-HT₁ agonists; Isopropanol; Drug discrimination; rat 55, 13
- Family and peer dysfunction;** Substance abuse liability; Hormonal and behavioral homeostasis; Personality 55, 165
- Fixed-interval schedule;** Methadone; Naloxone; Oral self-administration; Rhesus monkeys 55, 79
- Flunitrazepam;** Methadone maintenance; Benzodiazepines; Sedatives; IDU; Oxazepam; Diazepam; Motivation; Substance abuse 55, 63
- GABA_A positive modulators;** Ethanol; Pentobarbital; NMDA antagonists; 5-HT₁ agonists; Isopropanol; Drug discrimination; rat 55, 13
- Harm;** Ecstasy; Patterns of use; Polydrug use; Intervention preferences 55, 105
- Health;** Addiction; Bioavailability; Enantiomer; Intravenous; Methadone; Oral 55, 137
- Health-related service utilization;** HIV infected; Drug users; Risk behaviors 55, 69
- HIV infected;** Drug users; Risk behaviors; Health-related service utilization 55, 69
- Hormonal and behavioral homeostasis;** Substance abuse liability; Personality; Family and peer dysfunction 55, 165
- 5-HT₁ agonists;** Ethanol; Pentobarbital; GABA_A positive modulators; NMDA antagonists; Isopropanol; Drug discrimination; rat 55, 13
- Humans;** Cocaine; Drug abuse; Physiological effects; Behavioral effects 55, 1
- IDU;** Injecting drug use; School dropout; IVDU; African Americans; Level of education; Epidemiology 55, 177
- IDU;** Methadone maintenance; Benzodiazepines; Sedatives; Flunitrazepam; Oxazepam; Diazepam; Motivation; Substance abuse 55, 63
- Injecting drug use;** School dropout; IDU; IVDU; African Americans; Level of education; Epidemiology 55, 177
- Injuries;** Drug metabolites; Substance use 55, 53
- Intervention preferences;** Ecstasy; Patterns of use; Polydrug use; Harm 55, 105
- Intravenous;** Addiction; Bioavailability; Enantiomer; Health; Methadone; Oral 55, 137
- Isopropanol;** Ethanol; Pentobarbital; GABA_A positive modulators; NMDA antagonists; 5-HT₁ agonists; Drug discrimination; rat 55, 13
- IVDU;** Injecting drug use; School dropout; IDU; African Americans; Level of education; Epidemiology 55, 177
- Job strain;** Occupational health; Stress; Substance abuse; Survey 55, 45
- Level of education;** Injecting drug use; School dropout; IDU; IVDU; African Americans; Epidemiology 55, 177
- Matching;** Addiction; Algorithm; Automation; Criteria; Substance abuse 55, 35
- Measurement;** Adolescents; Assessment; Substance abuse; Comprehensive Adolescent Severity Inventory 55, 235
- Methadone;** Addiction; Bioavailability; Enantiomer; Health; Intravenous; Oral 55, 137
- Methadone;** Fixed-interval schedule; Naloxone; Oral self-administration; Rhesus monkeys 55, 79
- Methadone maintenance;** Benzodiazepines; Sedatives; IDU; Flunitrazepam; Oxazepam; Diazepam; Motivation; Substance abuse 55, 63
- Methadone maintenance therapy;** Substance abuse treatment; Treatment outcomes; Prognosis; Urinalyses 55, 25
- Motivation;** Methadone maintenance; Benzodiazepines; Sedatives; IDU; Flunitrazepam; Oxazepam; Diazepam; Substance abuse 55, 63
- Naloxone;** Fixed-interval schedule; Methadone; Oral self-administration; Rhesus monkeys 55, 79
- NMDA antagonists;** Ethanol; Pentobarbital; GABA_A positive modulators; 5-HT₁ agonists; Isopropanol; Drug discrimination; rat 55, 13
- Nurses;** Women; Prevalence; Substance use; Alcohol consequences 55, 145
- Occupational health;** Stress; Substance abuse; Survey; Job strain 55, 45
- Opioid maintenance;** Buprenorphine; Plasma level; Substance abuse 55, 157
- Opioids;** Addiction Research Center Inventory (ARCI); Spanish version; Subjective effects; Sedatives; Stimulants; Drug abuse 55, 117
- Oral;** Addiction; Bioavailability; Enantiomer; Health; Intravenous; Methadone 55, 137
- Oral self-administration;** Fixed-interval schedule; Methadone; Naloxone; Rhesus monkeys 55, 79
- Outcome;** Adolescent; Substance misuse; Treatment interventions 55, 247

- Outpatient;** Addiction; Clinical case management 55, 91
- Oxazepam;** Methadone maintenance; Benzodiazepines; Sedatives; IDU; Flunitrazepam; Diazepam; Motivation; Substance abuse 55, 63
- Partnership;** Substance misuse; Young people 55, 263
- Patterns of use;** Ecstasy; Polydrug use; Harm; Intervention preferences 55, 105
- Pentobarbital;** Ethanol; GABA_A positive modulators; NMDA antagonists; 5-HT₁ agonists; Isopropanol; Drug discrimination; rat 55, 13
- Perinatal exposure;** Cannabinoids; Δ^9 -Tetrahydrocannabinol; Cannabinoid receptor binding; Cannabinoid receptor mRNA levels 55, 127
- Personality;** Substance abuse liability; Hormonal and behavioral homeostasis; Family and peer dysfunction 55, 165
- Physiological effects;** Cocaine; Humans; Drug abuse; Behavioral effects 55, 1
- Plasma level;** Buprenorphine; Substance abuse; Opioid maintenance 55, 157
- Polydrug use;** Ecstasy; Patterns of use; Harm; Intervention preferences 55, 105
- Prevalence;** Adolescent; Substance use; Tobacco; Alcohol; Epidemiology 55, 187
- Prevalence;** Nurses; Women; Substance use; Alcohol consequences 55, 145
- Prognosis;** Substance abuse treatment; Treatment outcomes; Methadone maintenance therapy; Urinalyses 55, 25
- rat;** Ethanol; Pentobarbital; GABA_A positive modulators; NMDA antagonists; 5-HT₁ agonists; Isopropanol; Drug discrimination 55, 13
- Rhesus monkeys;** Fixed-interval schedule; Methadone; Naloxone; Oral self-administration 55, 79
- Risk behaviors;** HIV infected; Drug users; Health-related service utilization 55, 69
- Risk factors;** Adolescent; Substance use 55, 209
- School dropout;** Injecting drug use; IDU; IVDU; African Americans; Level of education; Epidemiology 55, 177
- Sedatives;** Addiction Research Center Inventory (ARCI); Spanish version; Subjective effects; Stimulants; Opioids; Drug abuse 55, 117
- Sedatives;** Methadone maintenance; Benzodiazepines; IDU; Flunitrazepam; Oxazepam; Diazepam; Motivation; Substance abuse 55, 63
- Spanish version;** Addiction Research Center Inventory (ARCI); Subjective effects; Sedatives; Stimulants; Opioids; Drug abuse 55, 117
- Stimulants;** Addiction Research Center Inventory (ARCI); Spanish version; Subjective effects; Sedatives; Opioids; Drug abuse 55, 117
- Stress;** Occupational health; Substance abuse; Survey; Job strain 55, 45
- Stroop paradigm;** Cognitive processing; Alcohol; Drinkers; Alcohol cues 55, 85
- Subjective effects;** Addiction Research Center Inventory (ARCI); Spanish version; Sedatives; Stimulants; Opioids; Drug abuse 55, 117
- Substance abuse;** Addiction; Algorithm; Automation; Criteria; Matching 55, 35
- Substance abuse;** Adolescents; Assessment; Measurement; Comprehensive Adolescent Severity Inventory 55, 235
- Substance abuse;** Buprenorphine; Plasma level; Opioid maintenance 55, 157
- Substance abuse liability;** Hormonal and behavioral homeostasis; Personality; Family and peer dysfunction 55, 165
- Substance abuse;** Methadone maintenance; Benzodiazepines; Sedatives; IDU; Flunitrazepam; Oxazepam; Diazepam; Motivation 55, 63
- Substance abuse;** Occupational health; Stress; Survey; Job strain 55, 45
- Substance abuse treatment;** Treatment outcomes; Prognosis; Methadone maintenance therapy; Urinalyses 55, 25
- Substance misuse;** Adolescent; Treatment interventions; Outcome 55, 247
- Substance misuse;** Comorbid disorders; Early identification and treatment 55, 225
- Substance misuse;** Partnership; Young people 55, 263
- Substance use;** Adolescent; Tobacco; Alcohol; Prevalence; Epidemiology 55, 187
- Substance use;** Drug metabolites; Injuries 55, 53
- Substance use;** Nurses; Women; Prevalence; Alcohol consequences 55, 145
- Substance use;** Risk factors; Adolescent 55, 209
- Survey;** Occupational health; Stress; Substance abuse; Job strain 55, 45
- Δ^9 -Tetrahydrocannabinol;** Cannabinoids; Perinatal exposure; Cannabinoid receptor binding; Cannabinoid receptor mRNA levels 55, 127
- Tobacco;** Adolescent; Substance use; Alcohol; Prevalence; Epidemiology 55, 187
- Treatment interventions;** Adolescent; Substance misuse; Outcome 55, 247
- Treatment outcomes;** Substance abuse treatment; Prognosis; Methadone maintenance therapy; Urinalyses 55, 25
- Urinalyses;** Substance abuse treatment; Treatment outcomes; Prognosis; Methadone maintenance therapy 55, 25
- Women;** Nurses; Prevalence; Substance use; Alcohol consequences 55, 145
- Young people;** Substance misuse; Partnership 55, 263

